Fleischer D.M.,American Academy of Allergy |
Sicherer S.,American Academy of Pediatrics AAP |
Greenhawt M.,The American College |
Campbell D.,Australasian Society of Clinical Immunology and Allergy ASCIA |
And 7 more authors.
Pediatrics | Year: 2015
The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma &Immunology, American Academy of Pediatrics, American College of Allergy, Asthma &Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Allergy and Clinical Immunology. © 2015 by the American Academy of Pediatrics. Source
Dalan D.,American Academy of Allergy
Current Opinion in Allergy and Clinical Immunology | Year: 2010
Purpose of review: More data are anticipated from the expected increase in use of electronic health records (EHRs). Upcoming initiatives require reporting of quality measures, meaningful use of clinical decision support, alert systems, and pharmacovigilance - knowledge resulting through use of EHRs. Data mining is a new tool that will help us manage information and derive knowledge from these data, and is a part of evolving new disciplines of informatics and knowledge management. Recent findings: Studies are reported from smaller clinic data marts to larger repositories and warehouses in various health systems, biomedical registries, and the medical literature on the Internet. Data mining technologies show promise and challenges. Outcome measures as structured data and narrative text can be mined with human assistance and newer automated natural language processing software. Despite advances, the growing diversity of clinic EHRs lack integration and interoperability with Internet-based biomedical databases. Summary: Allergists have the capability to mine clinic EHRs to discover new information, which may be hidden in charts. A central allergy computer can serve not just as a registry but also allows functionalities to enable EHRs' meaningful use. Harmonization of technological and organizational standards will allow seamless use of new natural language processing (NLP) tools and ontologies through a semantic web. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source
Rich R.R.,University of Alabama at Birmingham |
Fleisher T.A.,American Academy of Allergy |
Fleisher T.A.,U.S. National Institutes of Health |
Fleisher T.A.,Uniformed Services University of the Health Sciences |
And 5 more authors.
Clinical Immunology: Principles and Practice: Fourth Edition | Year: 2012
Offer your patients the best possible care with clear, reliable guidance from one of the most respected and trusted resources in immunology. Authoritative answers from internationally renowned leaders in the field equip you with peerless advice and global best practices to enhance your diagnosis and management of a full range of immunologic problems. "This is a must have book for any serious student of clinical immunology Reviewed by: British Journal of Immunology Date: December 2013. © 2013, Elsevier Limited. All rights reserved. Source
Many hay fever sufferers are turning to over-the-counter allergy medications to relieve their symptoms, but they may not be happy with the results they are getting from these medicines, a new study reveals. By comparison, fewer people treat their seasonal allergies with prescription medications, the researchers found. However, these patients report slightly higher levels of satisfaction with these medications, compared with users of over-the-counter allergy products, according to the findings, which will be presented Monday (Nov. 9) at the American Academy of Allergy, Asthma and Immunology annual meeting in San Antonio. The researchers found that 51 percent of adults who took a prescription allergy pill said they were very or extremely satisfied with the drug's effectiveness, while only 33 percent of adults who take an allergy pill sold over-the-counter reported this same degree of satisfaction with their treatment. Despite not being thrilled with the results, 62 percent of the adults surveyed said they use over-the-counter allergy products to manage their symptoms. It's not surprising that so many people take over-the-counter allergy medications, and the reason has a lot to do with the cost, said study author Dr. Eli Meltzer, a senior associate at Allergy & Asthma Medical Group & Research Center in San Diego. More and more allergy products are being approved by the U.S. Food and Drug Administration for sale over-the-counter, Meltzer said. Health plans may also be limiting people's access to prescription allergy medications until they have tried over-the-counter medications first, he said. [9 Myths About Seasonal Allergies] For the study, the researchers conducted a nationwide survey in March of 500 adults and 501 children ages 12 to 17, all of whom had been diagnosed by a doctor with allergic rhinitis, also known as hay fever. Most participants (80 percent) said they had moderate to severe symptoms of seasonal allergies in the spring, summer and fall. Both adults and children were more likely to take an over-the-counter pill for their allergies. The next most popular product was prescription nasal sprays, the study found. Adults typically saw their primary care doctor for allergy treatment, and children usually saw their pediatricians for allergy care. The study also found that only 14 percent of adults and 24 percent of children saw an allergy specialist for treatment. Seasonal allergies are often underdiagnosed, undertreated and undercontrolled, Meltzer told Live Science. It's not unusual for people to have allergy symptoms and just tolerate them, and do nothing about them, he said. People may self-treat their seasonal allergies without consulting their doctor, or choose a product they saw advertised on TV or that was recommended by a friend, Meltzer said. But people do not need to suffer with allergy symptoms that might affect their sleep, work, social lives and quality of life, Meltzer said. There are ways for most hay fever sufferers to control their symptoms, but patients have to be properly treated, Meltzer said. Medications can ease symptoms, or allergy shots, also known as immunotherapy, can provide long-term relief, he said. Over-the-counter products may help, but if symptoms are still bothersome, an allergy specialist may be able to help by managing and monitoring treatment, Meltzer said. Copyright 2015 LiveScience, a Purch company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Home > Press > Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016 Abstract: Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented additional preclinical data suggesting that ARC-F12, an RNAi therapeutic that inhibits the production of Factor XII (F12), has the potential to treat hereditary angioedema and to prevent thrombosis. Data presented in a poster at the 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI), show that ARC-F12 had the desired effects of significantly reduced swelling in a rat model of edema and inhibition of blood clot formation in a mouse model of thrombosis, without the undesired effect of increased bleeding risk. In a carrageenan-induced paw edema model in rats, treatment with ARC-F12 seven days prior to carrageenan challenge led to a significant reduction in edema (p < 0.001). The reduction in swelling in ARC-F12 treated rats is similar to that seen in rats treated with a kallikrein-targeted antibody. This supports Arrowhead's position that F12 inhibition could be an attractive target for the rare genetic disorder, hereditary angioedema (HAE). In a mouse model of thrombosis, a dramatic increase in occlusion times was observed in mice receiving ARC-F12. The time to blood flow occlusion is measured as a clinically relevant indicator of physiological response to F12 knockdown and is a measure of the inhibition of thrombus formation. Further, in multiple relevant models of bleeding risk, ARC-F12 did not cause an increase in bleeding times or bleeding risk. Anticoagulants can be used to reduce thrombus formation and thromboembolism occurrence, but also can cause an increase in serious bleeding risk. ARC-F12 may be able to reduce the risk of blood clot formation, without the undesirable bleeding risk caused by anticoagulants. In vivo studies in wild type mice showed that a single 2 mg/kg dose of ARC-F12 achieved greater than 95% knockdown of F12 levels. In multi-dose primate studies, a 4 mg/kg dose resulted in greater than 90% knockdown with even greater knockdown following subsequent doses. Knockdown was also highly durable with greater than 80% reduction maintained between monthly doses. ARC-F12 appeared to be generally well-tolerated and no drug-related changes in toxicity markers were observed as measured by clinical chemistry and hematologic parameters. F12 is a key component of the contact activation pathway involved in thrombosis and the kinin-kallekrein system involved in angioedema. It is predominantly produced in the liver and circulates in plasma, so Arrowhead believes that it is a uniquely suited target for an RNAi-therapeutic delivered with the proprietary Dynamic PolyconjugateTM (DPCTM) delivery system. Consistent with its process for all of its RNAi-therapeutic candidates, Arrowhead's discovery of ARC-F12 followed a screening funnel process that includes: bioinformatic selection of RNAi trigger sequences; trigger synthesis and in vitro screening; synthesis of cholesterol-RNAi triggers and in vivo screening; multiple iterations of structure-activity relationship (SAR) studies and in vivo screening to assess various chemical modifications to improve RNAi trigger activity; in vivo screening in non-human primates; efficacy testing in disease relevant models; non-GLP toxicology studies; and lastly, the selection of a lead candidate. About ARC-F12 Arrowhead's RNAi-based candidate ARC-F12 is in preclinical development as a potential treatment for factor XII (F12) mediated diseases. Arrowhead sees clear unmet need in hereditary angioedema (HAE) and thromboembolic diseases. The biology of factor 12 as part of the coagulation cascade and the kinin-kallikrein system suggest that its reduction through RNAi may present opportunities in both disease areas. The company is currently conducting studies in order to advance ARC-F12 into clinical trials. About Arrowhead Research Corporation Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma. For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit ir.arrowheadresearch.com/alerts.cfm. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.